| Andrew Wood is a Director in the Integrated Drug Substance Development team at Codiak BioSciences, which is focused on developing scalable production processes for exosomes and robust technology to load varied payloads into exosomes. Previously, Andrew worked at Voyager Therapeutics where he directed the downstream process development of rAAV products. Prior to moving into the gene therapy field, Andrew worked at Genzyme/Sanofi where he guided process validation activities for the commercial manufacturing of an enzyme replacement therapy. At the start of his industrial career, Andrew worked at Wyeth/Pfizer where he developed purification processes for mAbs, recombinant proteins, ADCs, and vaccines. Andrew received a B.S. in Chemical and Biological Engineering and M.S. in Biotechnology Engineering from Tufts University. |
